MBRX - Moleculin Bio shares surge 9% on Rare Pediatric status for WP1066 in ependymoma

The FDA has granted Rare Pediatric Disease Designation ((RPD)) to Moleculin Biotech's (MBRX) p-STAT3 inhibitor, WP1066, for the treatment of ependymoma, a rare type of tumor that can form in the brain or spinal cord.Rare Pediatric Disease status provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or it can be sold to a third party. WP1066 is an immune/transcription modulator capable of directly inhibiting certain key oncogenic transcription factors, including the activated form of a protein known as STAT3.WP1066 has also been shown in animal models to stimulate a natural immune response and immune memory to fight tumor progression.Shares rise 8.6% premarket, trading at $3.93.

For further details see:

Moleculin Bio shares surge 9% on Rare Pediatric status for WP1066 in ependymoma